Heron Therapeutics Inc. 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026 HERON THERAPEUTICS, INC. Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☑The number of shares of the registrant's common stock, par value $0.01 per share, outstanding as of May 6, 2026 was 189,279,369. HERON THERAPEUTICS, INC. FORM 10-QFOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026 TABLE OF CONTENTS PART I.FINANCIAL INFORMATION ITEM 1.Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three MonthsEnded March 31, 2026 and 2025 (Unaudited) Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the Three Months Ended Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and2025 (Unaudited)Notes to Condensed Consolidated Financial Statements (Unaudited)Management's Discussion and Analysis of Financial Condition and Results of OperationsQuantitative and Qualitative Disclosures about Market RiskControls and ProceduresPART II.OTHER INFORMATIONLegal ProceedingsITEM 1A.Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults upon Senior SecuritiesMine Safety DisclosuresOther InformationExhibitsSIGNATURES In this Quarterly Report on Form 10-Q, all references to "Heron," the "Company," "we," "us," "our" and similar terms refer toHeron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V. Heron Therapeutics®, the Heron logo, ZYNRELEF®, APONVIE®applicable intellectual property laws and are the property of Heron. All other trademarks appearing or incorporated by referenceinto this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarksreferred to in this Quarterly Report on Form 10-Q may appear without the ®, ™ orSMto indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicablelicensor to these trademarks. We do not intend our use or display of other parties' trademarks to imply, and such use or displayshould not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. 1 Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws.We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of1995, including section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the SecuritiesExchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify forward-looking statements by the use ofthe words "anticipate," "assume," "believe," "could," "estimate," "expect," "intend," "may," "might," "project," "should," "will,""would," and other expressions that predict or indicate future events and trends and which do not relate to historical matters. Allstatements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regardingour future results of operations and financial position, business and commercialization strategy, products and product candidates,research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, addressable Forward-looking statements include, but are not limited to, statements including: •our ability to successfully commercialize, market and achieve market acceptance of ZYNRELEF®meloxicam) extended-release solution ("ZYNRELEF"), APO